Latest Articles

Publication Date
All News Scientific
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.
Read Full Article
Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival - Bioengineer.org

Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival Bioengineer.org

Published: Oct. 14, 2025, 4:49 p.m.
Read Full Article
Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival - BIOENGINEER.ORG

Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival BIOENGINEER.ORG

Published: Oct. 14, 2025, 4:49 p.m.
Read Full Article
Combination of immunotherapy and chemotherapy as first-line treatment for advanced or recurrent endometrial cancer: a meta-analysis of phase 3 trials - BMC Cancer

Combination of immunotherapy and chemotherapy as first-line treatment for advanced or recurrent endometrial cancer: a meta-analysis of phase 3 trials BMC Cancer

Published: Oct. 14, 2025, 2:41 p.m.
Read Full Article
Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer - CancerNetwork

Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer CancerNetwork

Published: Oct. 13, 2025, 10:05 p.m.
Read Full Article
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial - Nature

Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial Nature

Published: Aug. 26, 2025, 11:43 a.m.
Read Full Article
Immunotherapy plus chemotherapy approved for endometrial cancer - The Pharmaceutical Journal

Immunotherapy plus chemotherapy approved for endometrial cancer The Pharmaceutical Journal

Published: Aug. 7, 2025, 2:48 p.m.
Read Full Article
Breakthrough treatment combines immunotherapy and chemotherapy - National Health Executive

Breakthrough treatment combines immunotherapy and chemotherapy National Health Executive

Published: Aug. 7, 2025, 8:48 a.m.
Read Full Article
Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights - Cureus

Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights Cureus

Published: July 30, 2025, 7:21 a.m.
Read Full Article
Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer - Medical Xpress

Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer Medical Xpress

Published: June 2, 2025, 6:20 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!